{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T14:24:50Z","timestamp":1648823090962},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T00:00:00Z","timestamp":1483142400000},"content-version":"vor","delay-in-days":1005,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.nrl.2012.12.008","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T04:20:04Z","timestamp":1362457204000},"page":"153-160","source":"Crossref","is-referenced-by-count":1,"title":["Factores determinantes del inicio de tratamiento con levodopa\/carbidopa\/entacapona en pacientes espa\u00f1oles con enfermedad de Parkinson"],"prefix":"10.1016","volume":"29","author":[{"given":"P.","family":"Mart\u00ednez-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ricart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2012.12.008_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/mds.10362","article-title":"Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain","volume":"18","author":"Benito-Leon","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.nrl.2012.12.008_bib0010","first-page":"641","article-title":"The prevalence and pharmacological cost of Parkinson's disease in Spain","volume":"43","author":"Abasolo-Osinaga","year":"2006","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0015","first-page":"1","article-title":"Diagnosis and treatment of Parkinson's disease: a systematic review of the literature","author":"Levine","year":"2003","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"10.1016\/j.nrl.2012.12.008_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","article-title":"Parkinson's disease: genetics and pathogenesis","volume":"6","author":"Shulman","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jnnp.2003.033530","article-title":"Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach","volume":"76","author":"Lewis","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrl.2012.12.008_bib0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00002512-200522090-00002","article-title":"Alternatives to levodopa in the initial treatment of early Parkinson's disease","volume":"22","author":"Lees","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.nrl.2012.12.008_bib0035","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q","article-title":"The initial treatment of Parkinson's disease should begin with levodopa","volume":"14","author":"Weiner","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.nrl.2012.12.008_bib0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jnnp.2006.098327","article-title":"A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis","volume":"78","author":"Grosset","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrl.2012.12.008_bib0045","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ana.20789","article-title":"Timing of treatment initiation in Parkinson's disease: a need for reappraisal?","volume":"59","author":"Schapira","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0050","first-page":"25","article-title":"Implications of the latest NICE Parkinson's disease guidance","volume":"102","author":"Beckford-Ball","year":"2006","journal-title":"Nurs Times"},{"key":"10.1016\/j.nrl.2012.12.008_bib0055","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","article-title":"Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease","volume":"13","author":"Horstink","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2012.12.008_bib0065","first-page":"203","article-title":"The management of patients with early Parkinson's disease","volume":"91","author":"Rascol","year":"2003","journal-title":"Adv Neurol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archneur.1995.00540300037010","article-title":"Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group","volume":"52","author":"McDermott","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression, and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2012.12.008_bib0080","first-page":"153","article-title":"Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale","volume":"2","author":"Fahn","year":"1987"},{"key":"10.1016\/j.nrl.2012.12.008_bib0085","series-title":"Third Symposium on Parkinson's disease","first-page":"152","article-title":"Projection technique for evaluating surgery in Parkinson's disease","author":"Schwab","year":"1969"},{"key":"10.1016\/j.nrl.2012.12.008_bib0090","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/mds.20916","article-title":"Metric attributes of the UPDRS 3.0 battery. Part I: feasibility, scaling assumptions, reliability, and precision","volume":"21","author":"Mart\u00ednez-Mart\u00edn","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.nrl.2012.12.008_bib0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non motor symptoms on health-related quality of life of patients with Parkinson's disease","volume":"26","author":"Mart\u00ednez-Mart\u00edn","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.nrl.2012.12.008_bib0100","first-page":"145","article-title":"Parkinson's disease. Diagnosis and the initiation of therapy","volume":"96","author":"Bhat","year":"2005","journal-title":"Minerva Med"},{"key":"10.1016\/j.nrl.2012.12.008_bib0105","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nrl.2012.12.008_bib0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/WNF.0b013e318065b088","article-title":"Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia","volume":"31","author":"Stacy","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/NDT.S1660","article-title":"Optimizing levodopa therapy for Parkinson's disease with levodopa\/carbidopa\/entacapone: implications from a clinical and patient perspective","volume":"4","author":"Brooks","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.nrl.2012.12.008_bib0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.22060","article-title":"Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease. The STRIDE-PD Study","volume":"68","author":"Stocchi","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":"Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nrl.2012.12.008_bib0130","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study","volume":"74","author":"Brooks","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrl.2012.12.008_bib0135","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","article-title":"Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease","volume":"61","author":"Olanow","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0140","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1468-1331.2009.02726.x","article-title":"Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis","volume":"16","author":"Nissinen","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0145","first-page":"46","article-title":"Early diagnosis of Parkinson's disease and initiation of treatment","volume":"5","author":"Weiner","year":"2008","journal-title":"Rev Neurol Dis"},{"key":"10.1016\/j.nrl.2012.12.008_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNF.0b013e31823dec73","article-title":"What factors influence motor complications in Parkinson disease?: a 10-year prospective study","volume":"35","author":"Garcia-Ruiz","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nrl.2012.12.008_bib0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mds.21878","article-title":"Quality of life in early Parkinson's disease treated with levodopa\/carbidopa\/entacapone","volume":"24","author":"Fung","year":"2009","journal-title":"Mov Disord"}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485313000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485313000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T08:29:26Z","timestamp":1539851366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485313000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0213485313000054"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2012.12.008","relation":{},"ISSN":["0213-4853"],"issn-type":[{"value":"0213-4853","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}